242 related articles for article (PubMed ID: 22862961)
1. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice.
Fosgerau K; Jessen L; Lind Tolborg J; Østerlund T; Schæffer Larsen K; Rolsted K; Brorson M; Jelsing J; Skovlund Ryge Neerup T
Diabetes Obes Metab; 2013 Jan; 15(1):62-71. PubMed ID: 22862961
[TBL] [Abstract][Full Text] [Related]
2. The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice.
Dalbøge LS; Almholt DL; Neerup TS; Vrang N; Jelsing J; Fosgerau K
J Pharmacol Exp Ther; 2014 Aug; 350(2):353-60. PubMed ID: 24902584
[TBL] [Abstract][Full Text] [Related]
3. The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats.
Skarbaliene J; Secher T; Jelsing J; Ansarullah ; Neerup TS; Billestrup N; Fosgerau K
Peptides; 2015 Jul; 69():47-55. PubMed ID: 25849341
[TBL] [Abstract][Full Text] [Related]
4. A GLP-1/glucagon (GCG)/CCK
Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N
Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823
[TBL] [Abstract][Full Text] [Related]
5. Stapled and
Chen X; Fu J; Zhou F; Yang Q; Wang J; Feng H; Jiang W; Jin L; Tang X; Jiang N; Yin J; Han J
J Med Chem; 2020 Nov; 63(21):12595-12613. PubMed ID: 33125843
[TBL] [Abstract][Full Text] [Related]
6. In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes.
Skarbaliene J; Rigbolt KT; Fosgerau K; Billestrup N
Eur J Pharmacol; 2017 Nov; 815():181-189. PubMed ID: 28928089
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis.
Fan R; Li X; Gu X; Chan JC; Xu G
Diabetes Obes Metab; 2010 Sep; 12(9):815-24. PubMed ID: 20649634
[TBL] [Abstract][Full Text] [Related]
8. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
[TBL] [Abstract][Full Text] [Related]
9. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
10. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
11. Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation.
Ma X; Hui H; Liu Z; He G; Hu J; Meng J; Guan L; Luo X
Diabetes Obes Metab; 2009 Oct; 11(10):953-65. PubMed ID: 19531053
[TBL] [Abstract][Full Text] [Related]
12. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
Moffett RC; Patterson S; Irwin N; Flatt PR
Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
[TBL] [Abstract][Full Text] [Related]
13. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
15. Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.
Shao Y; Yuan G; Feng Y; Zhang J; Guo X
Peptides; 2014 Feb; 52():134-42. PubMed ID: 24406898
[TBL] [Abstract][Full Text] [Related]
16. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain.
Hamilton A; Patterson S; Porter D; Gault VA; Holscher C
J Neurosci Res; 2011 Apr; 89(4):481-9. PubMed ID: 21312223
[TBL] [Abstract][Full Text] [Related]
17. Partial blockade of Kv2.1 channel potentiates GLP-1's insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice.
Sukma Rita R; Dezaki K; Kurashina T; Kakei M; Yada T
Endocrinology; 2015 Jan; 156(1):114-23. PubMed ID: 25337656
[TBL] [Abstract][Full Text] [Related]
18. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
19. [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
Consoli A; Di Biagio R
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):5-9. PubMed ID: 22158421
[TBL] [Abstract][Full Text] [Related]
20. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
